ADO Financials: Results, Ratios & Statements | Anteotech

ADO

Anteotech

Pharmaceuticals, Biotechnology & Life Sciences

Anteotech Ltd specializes in the development and commercialization of advanced medical diagnostics and energy storage solutions, leveraging its proprietary nanotechnology platform. It operates in healthcare and energy sectors, aiming for a significant market position through innovative solutions such as its proprietary AnteoBind™ technology, which enhances the sensitivity and performance of diagnostic assays.

Short position

short percentage0.00%

reported shorts1.3K

shares on issue3.265B

Anteotech (ASX:ADO) has 0.00% of its shares on issue reported as short positions as of 5 Oct 2026, or about 1,321 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.56% in February 2026. ADO is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

Latest result

Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency

Revenue: $530.8K (source: ASX (Markit))vs $968.9K (FY25); ASX (Markit), as at 8 Oct 2026
NPAT: −$5.4M (source: ASX (Markit))vs −$6.8M (FY25); ASX (Markit), as at 8 Oct 2026
EPS (diluted): −$0.002 (source: Derived: trailing 12 months at year end)vs −$0.003 (FY25); Derived: trailing 12 months at year end, as at 8 Oct 2026

Rev YoY: −45.2%FY
EPS YoY: n/aTTM

ASX (Markit)
Derived: trailing 12 months at year end

Summary of Annual Report to shareholders, 28 Sep 2026

AnteoTech reported FY2026 revenue of approximately $337,550 from product sales and development programs, though net profit was not disclosed and the company remains in a development stage. No dividend was declared. The company ended the year with $5.7 million cash on hand and $5.5 million in term deposits, and highlighted a 19% reduction in total cash expenses year-over-year, with a focus on commercialising its battery and life sciences technologies.

Automated summary of the filing; the filing itself is the record.

Key ratios

Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 9 Oct 2026

Gross margin: n/a
Operating margin: n/a
Net margin: −1,012.8%
FCF margin: n/a
ROE: n/a
ROA: n/a
FCF conversion: n/a
Net debt (excl. leases): n/a
Net debt / EBITDA: n/a
Current ratio: n/a
Interest cover: n/a
Cash dividends paid / net profit: n/a
Market cap: n/a (no share count we can vouch for)
P/E: n/a
P/B: n/a (no share count we can vouch for)

Ratios use the reporting currency (AUD); market cap is in AUD. Source: ASX (Markit), as at 8 Oct 2026.

Financial statements

Figures in AUD, the reporting currency; Yahoo Finance unless marked

ADO income, newest period first, figures in AUD
Line item	FY26	FY25	FY24	FY23
Revenue	$530.8K (source: ASX (Markit))	$968.9K	$460.4K	$365.7K
Gross profit	n/a	$968.9K	$460.4K	$365.7K
Operating income	n/a	−$9.2M	−$12.8M	−$13.4M
EBITDA	n/a	−$8.1M	−$11.7M	−$12.4M
EBIT	n/a	−$9.2M	−$12.8M	−$13.4M
Pretax income	n/a	−$6.8M	−$8.9M	−$12.7M
Tax	n/a	$0	$0	$0
NPAT	−$5.4M (source: ASX (Markit))	−$6.8M	−$8.9M	−$12.7M
Net interest income	n/a	−$5.3K	$11.5K	$9.3K
EPS basic	−$0.002 (source: Derived: trailing 12 months at year end)	−$0.003	−$0.004	−$0.006
EPS diluted	−$0.002 (source: Derived: trailing 12 months at year end)	−$0.003	−$0.004	−$0.006
Shares	n/a	2.71B	2.49B	2.07B

ASX (Markit)
Derived: trailing 12 months at year end

Financial reports

The company's own filings, newest first

Showing 10 of 107 reports